Statin use and decline in gait speed in community-dwelling older adults

Journal of the American Geriatrics Society

Volumn 63, Issue 1, 2015, Pages 124-129

  Lo Ciganic, Wei Hsuan ^a   Perera, Subashan ^b   Gray, Shelly L ^c   Boudreau, Robert M ^d   Zgibor, Janice C ^d   Strotmeyer, Elsa S ^d   Donohue, Julie M ^e   Bunker, Clareann H ^d   Newman, Anne B ^b,d   Simonsick, Eleanor M ^f   Bauer, Douglas C ^g   Satterfield, Suzanne ^h   Caserotti, Paolo ⁱ   Harris, Tamara ^f   Shorr, Ronald I ^j   Hanlon, Joseph T ^a,b,d,j,k  

^a Health Policy Institute   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Department of Epidemiology ^*  (United States)

^e UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^f NATIONAL INSTITUTE ON AGING   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

ⁱ UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^j GERIATRIC RESEARCH EDUCATION AND CLINICAL CENTER   (United States)

^k Center for Health Equity Research   (United States)

more..

Author keywords

Aged; Gait speed; Hydroxymethylglutaryl CoA reductase inhibitors; Physical function; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRESCRIPTION DRUG;

AGED; ALCOHOL CONSUMPTION; ARTICLE; CAUCASIAN; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; COMMUNITY LIVING; CONGESTIVE HEART FAILURE; DETERIORATION; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG USE; EXERCISE; FEMALE; GAIT; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIPOPHILICITY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRESCRIPTION; VELOCITY; BODY COMPOSITION; DOSE RESPONSE; DRUG EFFECTS;

AGED; BODY COMPOSITION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GAIT; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LONGITUDINAL STUDIES; MALE;

EID: 84925233035     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/jgs.13134     Document Type: Article

References (30)

1. Abellan van Kan G, Rolland Y, Andrieu S et al. Gait speed at usual pace as a predictor of adverse outcomes in community-dwelling older people an International Academy on Nutrition and Aging (IANA) Task Force. J Nutr Health Aging 2009;13:881-889.
2. Studenski S, Perera S, Patel K et al. Gait speed and survival in older adults. JAMA 2011;305:50-58.
3. Corsonello A, Garasto S, Abbatecola AM et al. Targeting inflammation to slow or delay functional decline: Where are we? Biogerontology 2010;11:603-614.
4. Bu DX, Griffin G, Lichtman AH. Mechanisms for the anti-inflammatory effects of statins. Curr Opin Lipidol 2011;22:165-170.
5. Giri J, McDermott MM, Greenland P et al. Statin use and functional decline in patients with and without peripheral arterial disease. J Am Coll Cardiol 2006;47:998-1004.
6. McDermott MM, Guralnik JM, Greenland P et al. Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation 2003;107:757-761.
7. Mondillo S, Ballo P, Barbati R et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med 2003;114:359-364.
8. Mohler ER III, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 2003;108:1481-1486.
9. Gray SL, Boudreau RM, Newman AB et al. Angiotensin-converting enzyme inhibitor and statin use and incident mobility limitation in community-dwelling older adults: The Health, Aging and Body Composition study. J Am Geriatr Soc 2011;59:2226-2232.
10. Gray SL, Aragaki AK, LaMonte MJ et al. Statins, angiotensin-converting enzyme inhibitors, and physical performance in older women. J Am Geriatr Soc 2012;60:2206-2214.
11. LaCroix AZ, Gray SL, Aragaki A et al. Statin use and incident frailty in women aged 65 years or older: Prospective findings from the Women's Health Initiative Observational Study. J Gerontol A Biol Sci Med Sci 2008;63A:369-375.
12. Haerer W, Delbaere K, Bartlett H et al. Relationships between HMG-CoA reductase inhibitors (statin) use and strength, balance and falls in older people. Intern Med J 2012;42:1329-1334.
13. Dumurgier J, Singh-Manoux A, Tavernier B et al. Lipid-lowering drugs associated with slower motor decline in the elderly adults. J Gerontol A Biol Sci Med Sci 2014;69A:199-206.
14. Perera S, Mody SH, Woodman RC et al. Meaningful change and responsiveness in common physical performance measures in older adults. J Am Geriatr Soc 2006;54:743-749.
15. Simonsick EM, Newman AB, Nevitt MC et al. Measuring higher level physical function in well-functioning older adults: Expanding familiar approaches in the Health ABC study. J Gerontol A Biol Sci Med Sci 2001;56A:M644-M649.
16. Pahor M, Chrischilles EA, Guralnik JM et al. Drug data coding and analysis in epidemiologic studies. Eur J Epidemiol 1994;10:405-411.
17. Jones PH, Davidson MH, Stein EA et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR∗Trial). Am J Cardiol 2003;92:152-160.
18. Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: Relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 1998;19:26-37.
19. National Institutes of Health. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421.
20. Fried LF, Boudreau R, Lee JS et al. Kidney function as a predictor of loss of lean mass in older adults: Health, Aging and Body Composition Study. J Am Geriatr Soc 2007;55:1578-1584.
21. Scott D, Blizzard L, Fell J et al. Statin therapy, muscle function and falls risk in community-dwelling older adults. QJM 2009;102:625-633.
22. Teng EL, Chui HC. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry 1987;48:314-318.
23. Radloff LS. The CES-D Scale: A self-report depression scale for research in the general population. Appl Psychol Meas 1977;1:385-401.
24. Peron EP, Gray SL, Hanlon JT. Medication use and functional status decline in older adults: A narrative review. Am J Geriatr Pharmacother 2011;9:378-391.
25. Schneeweiss S, Wang PS, Avorn J et al. Improved comorbidity adjustment for predicting mortality in Medicare populations. Health Serv Res 2003;38:1103-1120.
26. Shrank WH, Patrick AR, Brookhart MA. Healthy user and related biases in observational studies of preventive interventions: A primer for physicians. J Gen Intern Med 2011;26:546-550.
27. nd Ed. New York: Oxford University Press Inc., 2002.
28. Stone NJ, Robinson J, Lichtenstein AH et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:2889-2934.
29. Thompson PD, Clarkson PM, Rosenson RS. An assessment of statin safety by muscle experts. Am J Cardiol 2006;97:69C-76C.
30. Bruckert E, Hayem G, Dejager S et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study. Cardiovasc Drugs Ther 2005;19:403-414.